Skip to main content
. 2017 Nov 11;8(62):105819–105831. doi: 10.18632/oncotarget.22402

Table 2. Marker metabolites found in OPLS-DA models of 1H NMR-based urine metabolic profiling between stage I/II CRC patients and EC patients.

Metabolites Chemical shift (ppm) I/II stage of CRC vs EC Related metabolomic pathway
VIPa p-valueb Variations vs EC
Thymidine 6.28(t)
7.63(s)
1.82
1.36
0.000
0.033

Nucleotide metabolism
Fumarate 6.51(s) 1.71 0.000 TCA cycle, Arginine and Proline metabolism, Aspartate metabolism
Hippurate 7.54(m)
7.62(tt)
1.47
1.52
0.036
0.019

Gut microflora metabolism
cis-Aconitate 6.58(s) 1.69 0.000 TCA cycle, Glyoxylate, Dicarboxylate metabolism
Pyridoxic acid 7.53(s)
4.51(s)
1.62
1.50
0.003
0.000

Vitamin B6 metabolism
Cinnamic acid 6.51(d)
7.39(d)
7.44(m)
7.61(dd)
1.71
1.31
1.62
1.53
0.000
0.022
0.001
0.019



unknown
Homogentisic acid 6.71(m) 1.23 0.000 Phenylalanine and tyrosine metabolism, Disulfiram pathway
Indoleacetate 7.24(m)
7.50(d)
7.62(d)
1.23
1.47
1.18
0.002
0.009
0.004

Amino acid metabolism, Tryptophan metabolism
Trigonelline 8.83(m) 1.42 0.043 Vitamin metabolism
Creatinine 3.03(s)
4.05(s)
1.67
1.25
0.000
0.008

Urea metabolism, Creatinine metabolism
Creatine 3.02(s) 1.67 0.000 Urea metabolism, Creatine metabolism
Uracil 5.79(d) 1.47 0.003 Pyrimidine metabolism
Urea 5.78(br, s) 1.41 0.003 Urea metabolism

a: Variable importance in the projection (VIP) was obtained from OPLS-DA with a threshold of 1.0.

b: p value was calculated from Mann-Whitney U test.